Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

161.

EXAMINATION of new drug-eluting stents--top of the class!

Lancet.
Bhatt DL.
| Oct 27, 2012
162.

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Lancet.
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, Zucchiatti N.
| Oct 20, 2012
163.

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Lancet.
Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA.
| Oct 13, 2012
164.

How much CABG is good for us?

Lancet.
Jones DS.
| Aug 11, 2012
165.

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Lancet.
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ.
| Aug 11, 2012
167.

Comprehensive clinical care for men who have sex with men: an integrated approach.

Lancet.
Mayer KH, Bekker LG, Stall R, Grulich AE, Colfax G, Lama JR.
| Jul 28, 2012
168.

Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy.

Lancet.
Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Alkandari JR.
| Jul 21, 2012
169.

Cholera.

Lancet.
Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB.
| Jun 30, 2012
170.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Lancet.
Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK, Akil B.
| Jun 30, 2012
171.

Pulmonary embolism and deep vein thrombosis.

Lancet.
Goldhaber SZ, Bounameaux H.
| May 12, 2012
172.

Are we ready to recommend aspirin for cancer prevention?

Lancet.
Chan AT, Cook NR.
| Apr 28, 2012
173.

Towards regenerative therapy for cardiac disease.

Lancet.
Ptaszek LM, Mansour M, Ruskin JN, Chien KR.
| Mar 10, 2012
174.

Improving medication safety.

Lancet.
Schnipper JL, Rothschild JM.
| Apr 7, 2012
175.

Survival of children with burn injuries.

Lancet.
Tompkins RG.
| Mar 17, 2012
176.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Lancet.
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, Lerzo G.
| Feb 18, 2012
177.

β-agonists for ARDS: the dark side of adrenergic stimulation?

Lancet.
Thompson BT.
| Jan 21, 2012
178.

Bioartificial tissues and organs: are we ready to translate?

Lancet.
Ott HC, Mathisen DJ.
| Dec 10, 2011
179.

Statins and safety: can we finally be reassured?

Lancet.
Kohli P, Cannon CP.
| Dec 10, 2011
180.

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

Lancet.
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C.
| Jan 7, 2012